Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,235 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sars-CoV2 Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students

NCT04620798
View directory record Official record
Conditions
SARS-CoV-2, Serology, Students
Interventions
Immediate vs. delayed provision of antibody test results
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 100 Years
Enrollment
1,076 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Oct 24, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Results available

Fostamatinib for Hospitalized Adults With COVID-19

NCT04579393
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Placebo, fostamatinib
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 24, 2026, 2:28 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Safety and Efficacy of Baricitinib for COVID-19

NCT04340232
View directory record Official record
Conditions
COVID-19
Interventions
Baricitinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 24, 2026, 2:28 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Long COVID Immune Profiling

NCT06027255
View directory record Official record
Conditions
Long COVID, POTS - Postural Orthostatic Tachycardia Syndrome, Autonomic Dysfunction
Interventions
IL-6, cytokines (IL-17, and IFN-ɣ), Compass 31
Diagnostic Test · Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 2:28 PM EDT
Completed No phase listed Observational

Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies

NCT04748185
View directory record Official record
Conditions
Monoclonal B-Cell Lymphocytosis, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, B-cell Non Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 24, 2026, 2:28 PM EDT
Completed No phase listed Observational

COVID-19 Brain Injury

NCT04496076
View directory record Official record
Conditions
Sars-CoV2, Severe Neurologic Injury, Ischemic Stroke, Hemorrhagic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Traumatic Brain Injury, Status Epilepticus
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 24, 2026, 2:28 PM EDT
Completed Phase 4 Interventional

COVID-19 VaccinE Response in Rheumatology Patients

NCT05080218
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Interventions
Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab
Drug
Lead sponsor
Jeffrey Curtis
Other
Eligibility
18 Years to 85 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 24, 2026, 2:28 PM EDT
Terminated Phase 1 Interventional Results available

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

NCT05487040
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332 (nirmatrelvir)/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
52
States / cities
Huntsville, Alabama • Granada Hills, California • Inglewood, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 24, 2026, 2:28 PM EDT
Not listed Not applicable Interventional

[COVID-19] Reduction of Sars-CoV-2 Oral Viral Load With Prophylactic Mouth Rinse

NCT04719208
View directory record Official record
Conditions
Covid19
Interventions
Water (E) Mouth rinse with the solution provided, Chlorhexidine gluconate (A) Mouth rinse with the solution provided, Hydrogen peroxide (B) Mouth rinse with the solution provided, Betadine (C) Mouth rinse with the solution provided, Alcohol mouthwash (Listerine) (D) Mouth rinse with the solution provided
Other
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 24, 2026, 2:28 PM EDT
Completed No phase listed Observational

Effect of the COVID-19 Public Health Crisis on the Mental Health and Physical Well-Being of Cancer Patients, the Coping With COVID Study

NCT04652505
View directory record Official record
Conditions
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 24, 2026, 2:28 PM EDT
Not listed Not applicable Interventional

Cardiopulmonary Rehabilitation in COVID-19 Longhaulers

NCT04898205
View directory record Official record
Conditions
Covid19, Viral Syndrome
Interventions
Treadmill Exercise, Concentrated Oxygen, Concentrated Air
Other
Lead sponsor
Noah Greenspan
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 24, 2026, 2:28 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence

NCT04582903
View directory record Official record
Conditions
COVID-19 Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2031
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 24, 2026, 2:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

In Utero Exposure to SARS-CoV-2 (COVID-19) and Cardiovascular and Metabolic Endpoints in Early Life

NCT04921241
View directory record Official record
Conditions
In Utero SARS-CoV-2 Exposure
Interventions
In Utero Exposure to SARS-CoV-2
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
9 Months and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19

NCT04405570
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
Molnupiravir 200 mg, Molnupiravir 400 mg, Molnupiravir 800 mg, Placebo (PBO)
Drug
Lead sponsor
Ridgeback Biotherapeutics, LP
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Northridge, California • Oxnard, California • Yucaipa, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 24, 2026, 2:28 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults

NCT04668339
View directory record Official record
Conditions
Covid19, SARS-CoV Infection, Corona Virus Infection
Interventions
ARCT-021 single dose priming, ARCT-021 two lower dose priming, ARCT-021 two higher dose priming, Placebo (two doses), priming, Randomized booster, Placebo booster
Biological
Lead sponsor
Arcturus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
581 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Chandler, Arizona • Tucson, Arizona • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 24, 2026, 2:28 PM EDT
Completed No phase listed Observational

Ambulatory Management of Moderate to High Risk COVID-19 (SARS-CoV-2) Patients - The Coronavirus Related Outpatient Work Navigators (CROWN) Protocol

NCT04476602
View directory record Official record
Conditions
Covid-19 (SARS-CoV-2)
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 24, 2026, 2:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Prospective Virtual Study of Patient Reported Behaviors and Health Outcomes in Individuals With COVID-19

NCT05042232
View directory record Official record
Conditions
SARS-CoV-2 Acute Respiratory Disease
Interventions
SARS-CoV-2 Positive, SARS-CoV-2 Negative
Other
Lead sponsor
Everly Health
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 24, 2026, 2:28 PM EDT
Completed Phase 1 Interventional Results available

First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.

NCT04535167
View directory record Official record
Conditions
Viral Disease
Interventions
PF-07304814, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 79 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Mountain View, California • Newport Beach, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 24, 2026, 2:28 PM EDT
Completed No phase listed Observational

Registry of Sustained Immunity to COVID-19 Among ESKD Patients

NCT04495764
View directory record Official record
Conditions
SARS-CoV-2 Infection, Anti-SARS-CoV-2 Infection
Interventions
Not listed
Lead sponsor
Davita Clinical Research
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Victorville, California • Bridgeport, Connecticut • Minneapolis, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 24, 2026, 2:28 PM EDT
Completed Phase 2 Interventional

Probiotic Use for Recovery Enhancement From Long COVID-19

NCT06643299
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome
Interventions
Probiotic Agent, Placebo
Drug · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 24, 2026, 2:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Understanding Communications Included With COVID-19 (Corona Virus Disease of 2019) Home Testing Kits

NCT04758299
View directory record Official record
Conditions
COVID-19 Testing, Decision Making
Interventions
decision science-based design
Other
Lead sponsor
Barry Dewitt
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 24, 2026, 2:28 PM EDT
Terminated Phase 2 Interventional Results available

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

NCT04502433
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
CUROSURF® (poractant alfa)
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 24, 2026, 2:28 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine

NCT05067933
View directory record Official record
Conditions
COVID-19
Interventions
VXA-CoV2-1.1-S, Placebo Tablets
Drug · Other
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Long Beach, California • Wichita, Kansas • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 24, 2026, 2:28 PM EDT
Completed No phase listed Observational

An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib

NCT05594147
View directory record Official record
Conditions
Malignant Solid Tumors, Coronavirus Disease 2019 (COVID-19), SARS-CoV-2 Infection
Interventions
Non-TKIs, Other TKIs, Regorafenib (Stivarga, BAY73- 4506), Sorafenib (Nexavar, BAY43-9006)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 24, 2026, 2:28 PM EDT